CXCR4 and lung cancer: Treatment with AMD3100 (also known as Plerixafor and Mozobil), a bicyclam currently used in the mobilization of hematopoietic stem cells from the bone marrow [100], or TN14003/BKT140 were shown to disrupt CXCR4-mediated tumor cell adhesion to stromal cells and sensitize lung cancer cells to cytotoxic drugs [101,102].